Comanche Biopharma
Latest round
- Series B
Last raised
- Dec 2023
Total raised
- $38M
Investors
- 6
About Comanche Biopharma
Founded in 2020 by Mike Young and Thomas Scott Johnson, and based in Massachusetts, US, Comanche Biopharma Corp. operates as a biopharmaceutical company that develops siRNA therapy for the treatment of preeclampsia. In December 2023, Comanche Biopharma Corp. Comanche Biopharma specializes in developing an investigational siRNA medicine specifically aimed at addressing preterm preeclampsia, a severe pregnancy complication that poses significant risks to both mothers and infants. This therapeutic approach is designed to provide evidence-based solutions that cater to the urgent need for treatments in high-risk pregnancies. The company's primary target market includes healthcare providers, hospitals, and maternal-fetal medicine specialists who require reliable interventions to manage complications associated with pregnancy.
Who invested in Comanche Biopharma
6 investors across 1 round
See all investors in Comanche Biopharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Dec 14, 2023
Amount
$38M
Investors
Questions about Comanche Biopharma
Who invested in Comanche Biopharma?
Comanche Biopharma has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Comanche Biopharma raised?
Comanche Biopharma has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Comanche Biopharma last raise money?
Comanche Biopharma's most recent round on record is a Series B, in Dec 2023.
What does Comanche Biopharma do?
Founded in 2020 by Mike Young and Thomas Scott Johnson, and based in Massachusetts, US, Comanche Biopharma Corp.
Where is Comanche Biopharma headquartered?
Comanche Biopharma is headquartered in Concord, US.
Which VCs invest in companies like Comanche Biopharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Comanche Biopharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Comanche Biopharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.